Cover Image
市場調查報告書

輕度認知障礙 : 開發中產品分析

Mild Cognitive Impairment - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 253633
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
輕度認知障礙 : 開發中產品分析 Mild Cognitive Impairment - Pipeline Review, H1 2017
出版日期: 2017年04月11日 內容資訊: 英文 124 Pages
簡介

所謂輕度認知障礙(MCI)是指思考和辨識,記憶等認知功能產生問題的狀態。屬於介於隨著年齡認知能力下降,和更嚴重的癡呆症中間的輕度認知障礙。主要的症狀有憂鬱症和過敏症·攻擊性、焦慮症、無感情(沒精神)等。易罹病素質有糖尿病及高血壓、憂鬱症、吸煙、膽固醇上升等。

本報告提供全球各國的輕度認知障礙治療用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

輕度認知障礙概要

治療藥的開發

  • 輕度認知障礙開發中產品:概要
  • 各企業開發中的輕度認知障礙治療藥
  • 大學/研究機關研究中的輕度認知障礙治療藥
  • 開發中產品一覽(各企業)
  • 研究中產品一覽(各大學/研究機關)

輕度認知障礙:治療藥的評估

  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

輕度認知障礙開發治療藥的企業

  • AgeneBio Inc
  • Avraham Pharmaceuticals Ltd
  • CereSpir Inc
  • ConSynance Therapeutics Inc
  • Eisai
  • Eli Lilly and Company
  • Ensol Biosciences Inc
  • Genzyme Corp
  • IntelGenx Corp
  • Krenitsky Pharmaceuticals Inc
  • Merck & Co Inc
  • Nanotherapeutics Inc
  • Neuron Biopharma SA
  • NLS Pharma Group
  • Octapharma AG
  • Pfizer Inc
  • Sage Therapeutics Inc
  • SBI Pharmaceuticals Co Ltd
  • Suven Life Sciences Ltd
  • 武田藥品工業
  • Therapix Biosciences Ltd

藥物簡介

輕度認知障礙治療藥:開發暫停的產品

輕度認知障礙治療藥:開發中止的產品

輕度認知障礙相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9166IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2017, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 8, 7, 1, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mild Cognitive Impairment - Overview
    • Mild Cognitive Impairment - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Mild Cognitive Impairment - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Mild Cognitive Impairment - Companies Involved in Therapeutics Development
    • AgeneBio Inc
    • Avraham Pharmaceuticals Ltd
    • CereSpir Inc
    • ConSynance Therapeutics Inc
    • Eisai Co Ltd
    • Eli Lilly and Company
    • Ensol Biosciences Inc
    • Genzyme Corp
    • IntelGenx Corp
    • Krenitsky Pharmaceuticals Inc
    • Merck & Co Inc
    • Nanotherapeutics Inc
    • Neuron Biopharma SA
    • NLS Pharma Group
    • Octapharma AG
    • Pfizer Inc
    • Sage Therapeutics Inc
    • SBI Pharmaceuticals Co Ltd
    • Suven Life Sciences Ltd
    • Takeda Pharmaceutical Company Ltd
    • Therapix Biosciences Ltd
  • Mild Cognitive Impairment - Drug Profiles
    • aminolevulinic acid hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAN-2401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bosutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brexanolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSP-1103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSTI-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DAOI-B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elenbecestat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KP-544 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ladostigil tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levetiracetam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levofacetoperane - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3002813 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3303560 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • montelukast sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Moriah-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPS-0158 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPS-0163 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NST-0037 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NST-0076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NST-0078 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NTC-942 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sargramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-512 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVNI-1307014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-071 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tropisetron - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • verubecestat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XEN-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Mild Cognitive Impairment - Dormant Projects
  • Mild Cognitive Impairment - Discontinued Products
  • Mild Cognitive Impairment - Product Development Milestones
    • Featured News & Press Releases
      • Oct 31, 2016: Therapix Biosciences Successfully Completed the Development of a Formulation for a Tablet for Sublingual Administration of THC for Pharmaceutical Use
      • Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
      • Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast
      • Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment
      • Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
      • Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
      • Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI
      • Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON
      • May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment
      • Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m
      • Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer's Disease At ICAD 2009, Vienna, Austria.
      • Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland
      • Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London
      • Sep 29, 2008: Suven Completes Phase-I Clinical Trials Single Ascending Dose Of Suvn-502 In Switzerland
      • Sep 25, 2008: Suven Life Sciences Ltd. Announces DCGI Nod To Conduct Phase-I Clinical Trials Of Suvn-502 For Alzheimer'S Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Mild Cognitive Impairment, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Mild Cognitive Impairment - Pipeline by AgeneBio Inc, H1 2017
  • Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd, H1 2017
  • Mild Cognitive Impairment - Pipeline by CereSpir Inc, H1 2017
  • Mild Cognitive Impairment - Pipeline by ConSynance Therapeutics Inc, H1 2017
  • Mild Cognitive Impairment - Pipeline by Eisai Co Ltd, H1 2017
  • Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H1 2017
  • Mild Cognitive Impairment - Pipeline by Ensol Biosciences Inc, H1 2017
  • Mild Cognitive Impairment - Pipeline by Genzyme Corp, H1 2017
  • Mild Cognitive Impairment - Pipeline by IntelGenx Corp, H1 2017
  • Mild Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017
  • Mild Cognitive Impairment - Pipeline by Merck & Co Inc, H1 2017
  • Mild Cognitive Impairment - Pipeline by Nanotherapeutics Inc, H1 2017
  • Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H1 2017
  • Mild Cognitive Impairment - Pipeline by NLS Pharma Group, H1 2017
  • Mild Cognitive Impairment - Pipeline by Octapharma AG, H1 2017
  • Mild Cognitive Impairment - Pipeline by Pfizer Inc, H1 2017
  • Mild Cognitive Impairment - Pipeline by Sage Therapeutics Inc, H1 2017
  • Mild Cognitive Impairment - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017
  • Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd, H1 2017
  • Mild Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H1 2017
  • Mild Cognitive Impairment - Dormant Projects, H1 2017
  • Mild Cognitive Impairment - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Mild Cognitive Impairment - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Mild Cognitive Impairment, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top